GSK reports positive data from DREAMM-2 multiple myeloma trial

GSK submitted an application to the US Food and Drug Administration (FDA) seeking approval for belantamab mafodotin. Credit: GSK.



  • GSK reports positive data from DREAMM-2 multiple myeloma trial